Class 1, 2, and 3 BRAF -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Purpose: BRAF mutations are grouped in activating RAS-independent signaling as monomers (class 1–V600E) or as dimers (class 2–codons 597/601), and RAS-dependent with impaired kinase activity (class 3–codons 594/596). Although clinical, pathologic, and molecular features of V600EBRAF-mutated metastatic colorectal cancer (mCRC) are well known, limited data are available from the two other classes. Experimental Design: Data from 117 patients with BRAF (92 class 1, 12 class 2, and 13 class 3)-mutated mCRC were collected. A total of 540 BRAF wt mCRCs were included as control. IHC profiling was performed to determine the consensus molecular subtypes (CMS), cytokeratin 7/20 profiles, tumor-infiltrating lymphocyte infiltration, and BM1/BM2 categorization. Overall survival (OS) and progression-free survival were evaluated by Kaplan–Meier and log-rank test. Results: Class 3 BRAF-mutated mCRC was more frequently left sided (P = 0.0028), pN0 (P = 0.0159), and without peritoneal metastases (P = 0.0176) compared with class 1, whereas class 2 cases were similar to class 1. Hazard ratio for OS, as compared with BRAF wt, was 2.38 [95% confidence interval (CI), 1.61–3.54] for class 1, 1.90 (95% CI, 0.85–4.26) for class 2, and 0.93 (95% CI, 0.51–1.69) for class 3 (P < 0.0001). Class 2 and 3 tumors were all assigned to CMS2-3. A higher median CD3/CD8-positive lymphocyte infiltration was observed in BRAF-mutated class 2 (P = 0.033) compared with class 3 cases. Conclusions: For the first time, different clinical and pathologic features and outcome data were reported according to the three BRAF mutation classes in mCRC. Specific targeted treatment strategies should be identified in the near future for such patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421 · cited 1×
“Introduction Analysis of molecular alteration like RAS, BRAFmutation, andmicrosatellite instability are nowadays a consolidated routine in the assessment of patients with metastatic colorectal cancer (mCRC) (1) because all of them have a clear prognostic and/or predictive role.”
BackgroundTumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Yao, Z., Yaeger, R., Rodrik-Outmezguine, V. S., Tao, A., Torres, N. M., Chang, M. T., Drosten, M., Zhao, H., Cecchi, F., Hembrough, T., et al. (2017) · Nature · doi:10.1038/nature23291 · Cited by 562 · cited 2×
“Overall BRAFmutations occur in only 2% of patients with mCRC and cover 19 different codons (8, 9).”
BackgroundNew perspectives for targeting RAF kinase in human cancer
Karoulia, Z., Gavathiotis, E., & Poulikakos, P. I. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.79 · Cited by 404 · cited 2×
“Other Yes 60 (11) 12 (13) 1 (10) 3 (23) 0.”
BackgroundSveen, A., Bruun, J., Eide, P. W., Eilertsen, I. A., Ramirez, L., Murumägi, A., Arjama, M., Danielsen, S. A., Kryeziu, K., Elez, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1234 · Cited by 256 · cited 2×
“Recently Sveen and colleagues (17), investigated drug sensitivity according to CMS classification in preclinical models showing that CMS2 cell lines and PDX are more sensitive to EGFR and HER2 inhibition compared with other CMS subgroups.”
BackgroundTrinh, A., Trumpi, K., De Sousa E Melo, F., Wang, X., de Jong, J. H., Fessler, E., Kuppen, P. J. K., Reimers, M. S., Swets, M., Koopman, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0680 · Cited by 180
Cited by
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
ten Hoorn, S., de Back, T. R., Sommeijer, D. W., & Vermeulen, L. (2022) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab106 · Cited by 203
“Other reasons for exclusion after full text screening were no outcome data of interest reported (n=12) (7,42-50), no data on the individual CMSs reported (n=3) (51-53) or a study protocol (n=1) (54) (Figure 1).”
BackgroundEmerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks
Śmiech, M., Leszczyński, P., Kono, H., Wardell, C., & Taniguchi, H. (2020) · Genes · doi:10.3390/genes11111342 · Cited by 168
“Moreover, they confirmed that patients with class I and class II BRAF showed similar poor median overall survival (OS) and disease-free survival [34].”
BackgroundThe Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
Mauri, G., Bonazzina, E., Amatu, A., Tosi, F., Bencardino, K., Gori, V., Massihnia, D., Cipani, T., Spina, F., Ghezzi, S., et al. (2021) · Cancers · doi:10.3390/cancers13010137 · Cited by 73
Metadata
- Authors
- Schirripa, M., Biason, P., Lonardi, S., Pella, N., Pino, M. S., Urbano, F., Antoniotti, C., Cremolini, C., Corallo, S., Pietrantonio, F., Gelsomino, F., Cascinu, S., Orlandi, A., Munari, G., Malapelle, U., Saggio, S., Fontanini, G., Rugge, M., Mescoli, C., Lazzi, S., Reggiani Bonetti, L., Lanza, G., Dei Tos, A. P., De Maglio, G., Martini, M., Bergamo, F., Zagonel, V., Loupakis, F., & Fassan, M.
- Venue
- Clinical Cancer Research
- Published
- 2019-07-01
- Volume
- 25
- Issue
- 13
- Pages
- 3954-3961
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2938181692
- Cited by
- 102
- References
- 5
- FWCI
- 4.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Class 1, 2, and 3 BRAF -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-0311
- The paper
- Schirripa, M., Biason, P., Lonardi, S., Pella, N., Pino, M. S., Urbano, F., Antoniotti, C., Cremolini, C., Corallo, S., Pietrantonio, F., Gelsomino, F., Cascinu, S., Orlandi, A., Munari, G., Malapelle, U., Saggio, S., Fontanini, G., Rugge, M., Mescoli, C., . . . Fassan, M. (2019). Class 1, 2, and 3 BRAF -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-0311
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.